Merck KGaA acquires rights to PDS Biotech's technology; threatens action in Portugal

10 July 2012

Privately-held US biotech firm PDS Biotechnology says it has entered into an exclusive worldwide licensing agreement with Germany’s Merck KGaA (MRK: DE) for use of its novel Versamune nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in preclinical development.

Under the terms of the deal, PDS Biotech will receive an undisclosed upfront payment in cash, as well as development milestone payments, and commercial and sales milestone payments. The US firm will also receive royalties on sales of the products incorporating the technology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK